The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study

Headache

Volumn 38, Issue 3, 1998, Pages 173-183

  Cady, Roger K ^a  

^a HEADACHE CARE CENTER   (United States)

Author keywords

Long term study; Migraine; Zolmitriptan

Indexed keywords

SEROTONIN 1B AGONIST; ZOLMITRIPTAN;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO;

EID: 0031920915     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1998.3803173.x     Document Type: Article

References (28)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69.
2. Rasmussen BK. Epidemiology of headache. Cephalalgia. 1995;15:45-68.
3. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology. 1994;44(suppl 4):S17-S23.
4. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine, Int J Epidemiol. 1995;24:612-618.
5. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache. 1994;34:337-343.
6. Solomon GD. Quality of life assessment in patients with headache. Pharmacoeconomics. 1994;6:34-41.
7. Dahlöf CG, Dimenäs E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia. 1995;15:31-36.
8. Diener HC. A review of current treatments for migraine. Eur Neurol. 1994;34(suppl 2):18-25.
9. 1 receptors in migraine pathophysiology and treatment. Eur J Neurol. 1995;2:5-21.
10. 1D agonist drugs: selectively targeting additional sites of action. Eur Neurol. 1996;36(suppl 2):13-18.
11. Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992;43:776-798.
12. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
13. 1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain. 1996;67:355-359.
14. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P. The tolerability and pharmacokinetics of the novelantimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol. 1996;41:141-147.
15. Dixon R, Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia. 1997;17(suppl 18):15-20.
16. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan ('Zomig', 311C90) for the acute treatment of migraine. Neurology. 1997;48. In press.
17. Solomon GD, Cady RK, Klapper JA, Saper JR. Dose confirmation of zolmitriptan for the acute treatment of migraine. Neurology. 1997;48. In press.
18. Rapoport AM, Ward T, Katz DA, Sheftell FD. Zolmitriptan ("Zomig"): rapid onset of migraine relief. Cephalalgia. 1997;17:422. Abstract.
19. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
20. 1B/1D agonist. International clinic experience based on >3000 subjects treated with zolmitriptan. Cephalalgia. 1997:17(suppl 18):41-52.
21. Simmons VE, Blakeborough P. The safety profile of sumatriptan. Rev Contemp Pharmacother. 1994;5:319-328.
22. Tansey MJ, Pilgrim AJ, Martin PM. Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol. 1993;33:310-315.
23. Chester AH, Martin GR, Bodelsson M, et al. 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc Res. 1990; 24:932-937.
24. Giorgi L, Dixon R, Touw K. Cardiovascular safety of the novel anti-migraine compound 311C90. Cephalalgia. 1995;15(suppl 14):220. Abstract.
25. 1B/1D agonist: an overview of efficacy. Cephalalgia. 1997;17(suppl 18):28-40.
26. MacGregor EA. 'Menstrual' migraine: towards a definition. Cephalalgia. 1996;16:11-21.
27. Solbach P, Sargent J, Coyne L. Menstrual migraine headache: results of a controlled, experimental, outcome study of non-drug treatments. Headache. 1984;24:75-78.
28. 1B/1D agonist for migraine. Cephalalgia. 1997;17(suppl 18):4-14.